On­ly a small frac­tion of rare pe­di­atric des­ig­na­tions have led to vouch­ers, new FDA analy­sis shows

Out of hun­dreds of po­ten­tial drugs with rare pe­di­atric dis­ease des­ig­na­tions, on­ly 7% of them have won pri­or­i­ty re­view vouch­ers from the FDA, ac­cord­ing to an agency re­view of a decade’s worth of da­ta that are be­ing made pub­lic for the first time.

The analy­sis, pub­lished Mon­day in the Or­phanet Jour­nal of Rare Dis­eases, looked at 569 rare pe­di­atric dis­ease des­ig­na­tions from the FDA be­tween 2013 and the end of 2022. On­ly 38 des­ig­nat­ed prod­ucts have won pri­or­i­ty re­view vouch­ers, which are award­ed when these prod­ucts win ap­proval and the vouch­ers can be sold or used to speed up an­oth­er drug’s re­view time­line.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER